Anderer G, Schrappe M, Müller-Brechlin A, Lauten M, Muti P, Welte
K, Stanulla M. Polymorphisms within glutathione S-transferase genes and
initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.
Pharmacogenetics 2000, 10: 715-26.
Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000, 342- 998
Beltinger C, Boehler T, Karawajew L, Ludwig WD, Schrappe M, Debatin KM. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukemia.Br J Haematol 1998, 102-722
Beltinger C, Kurz E, Boehler T, Schrappe M, Ludwig WD, Debatin KM.CD95 (APO-1/FAS) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 1998, 91: 3943-51
Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood. 1997;90:571-7
Conter V, Schrappe M, Arico M, Reiter A, Rizzari C, Dordelmann M, Valsecchi MG, Zimmermann M, Ludwig WD, Basso G, Masera G, Riehm H. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin- Frankfurt-Munster groups. J Clin Oncol. 1997;15:2786-2791.
Creutzig U, Schrappe M. [Acute leukemia in childhood]. Internist. 1996;37:982-93
Doerdelmann M, Reiter A, Zimmermann M, Fengler R, Henze G, Riehm H, Schrappe M. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood ALL. J Pediatr Hematol Oncol 1998, 20: 444
Doerdelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, Lampert F, Niemeyer C, Harbott J, Ritter J, Dorffel W, Nessler G, Kühl J, Riehm H. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Leukemia 1998, 12: 645
Dördelmann M, Reiter A, Borkhardt A, Ludwig W-D, Götz N, Viehmann S, Gadner H, Riehm H, Schrappe M. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999, 94: 1209-17
Dordelmann M, Reiter A, Zimmermann M, Fengler R, Henze G, Riehm H, Schrappe M. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1998;20:444-50.
Dordelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, Lampert F, Harbott J, Niemeyer C, Ritter J, Dorffel W, Nessler G, Kuhl J, Riehm H. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia. 1998;12:645-51.
Harbott J, Ritterbach J, Ludwig WD, Bartram CR, Reiter A, Lampert F. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. Recent Results Cancer Res. 1993;131:123-32
Hiddemann W, Harbott J, Ludwig WD, Ritter J, Nehmer A, Reiter A, Kolkmeyer A, Laing T, Riehm H. DNA aneuploidy in childhood acute lymphoblastic leukemia: relation to clinical determinants and prognosis within four consecutive BFM trials. Recent Results Cancer Res. 1993;131:113-21
Kamps WA, Bökkerink JPM, Hählen K, Hermans J, Riehm H, Gadner H, Schrappe M, Slater R, van den Berg-de Ruiter E, Smets LA, de Vaan GAM, Weening RS, van Weerden JF, van Wering ER, van der Does-van den Berg A. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM 86 without cranial radiotherapy: Results of DCLSG protocol ALL-7 (1988-1991). Blood 1999, 94: 1226-36
Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia. 2002;16:1437-42.
Lauten M, Stanulla M, Zimmermann M, Welte K, Riehm H, Schrappe M. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr. 2001;213:169-74.
Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, Schrappe M. Secondary neoplasms subsequent to BFM therapy of childhood acute lymphoblastic leukaemia: Significantly lower risk without cranial radiotherapy. Blood 2000, 95: 2770-5
Ludwig WD, Harbott J, Bartram CR, Komischke B, Sperling C, Teichmann JV, Seibt-Jung H, Notter M, Odenwald E, Nehmer A. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Recent Results Cancer Res. 1993;131:269-82
Mielcarek M, Sperling C, Schrappe M, Meyer U, Riehm H, Ludwig WD. Expression of intercellular adhesion molecule 1 (ICAM-1) in childhood acute lymphoblastic leukaemia: correlation with clinical features and outcome. Br J Haematol. 1997;96:301-7
Muller HJ, Beier R, Loning L, Blutters-Sawatzki R, Dorffel W, Maass E, Muller-Weihrich S, Scheel-Walter HG, Scherer F, Stahnke K, Schrappe M, Horn A, Lumkemann K, Boos J. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br.J Haematol. 2001;114:794-9
Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359:1909-15
Ratei R, Sperling C, Karawajew L, Schott G, Schrappe M, Harbott J, Riehm H, Ludwig W-D. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia. Ann Hematol 1998, 77: 107
Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122-33
Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, Niemeyer CM, Gadner H, Muller-Weihrich S, Ritter J. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992;80:2471-8
Riehm H, Gadner H, WeIte K. Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes - Erfahrungsbericht nach 6 Jahren [The west-berlin therapy study of acute lymphoblastic leukemia in childhood--report after 6 years (author's transl)]. Klin Padiatr. 1977; 189: 89-102
Riehm H, Gadner H, Henze G, Langermann H-J, Odenwald E. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol. 1980; 2: 299-306
Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G. Therapy results in five ALL-BFM studies since 1970: Implications of risk factors für prognosis. Hematol Bluttransfus. 1987; 30: 139-46
Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein H, Ludwig R, Ritter J, Stollmann B, Henze G. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) [The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83)]. Klin Pädiatr. 1987; 199: 151-60
Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Hamatol Bluttransfus. 1990; 33: 439-50
Ritter J, Schrappe M. Clinical features and therapy of lymphoblastic leukemia. In: Lilleyman JS, Hann IM, Blanchette VS (eds): Paediatric Hematology, London, Curchill Livingstone, 1999, 537
Ritterbach J, Hiddemann W, Beck JD, Schrappe M, Janka-Schaub G, Ludwig WD, Harbott J, Lampert F. Detection of hyperdiploid karyotypes (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) using fluorescence in situ hybridization (FISH).Leukemia 1998, 12: 427
Schoch C, Rieder H, Freund M, Hoelzer D, Riehm H, Fonatsch C. Twenty-three cases of acute lymphoblastic leukemia with translocation t(4;11)(q21;q23): the implication of additional chromosomal aberrations. Ann Hematol. 1995;70:195-201
Schott G, Sperling C, Schrappe M, Ratei R, Martin M, Meyer U, Dörken B, Riehm H, Ludwig W-D. Immunophenotypic and clinical features of T-cell receptor (TCR) gamma/delta+ T lineage acute lymphoblastic leukaemia. Br J Haematol 1998, 101: 753
Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V, Reiter A, Valsecchi MG, Gadner H, Basso G, Bartram CR, Lampert F, Riehm H, Masera G. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998;92:2730-41
Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub G, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:2193-2194
Schrappe M, Creutzig U. Akute Leukämien.In Reinhardt D, Creutzig U, Kiess W, Luthardt T, Michalk D, Schmidt E, Ulmer H (eds): Leitlinien Kinderheilkunde und Jugendmedizin, München, Jena, Urban & Fischer, 1999, 78
Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Khl J, Gadner H, Havers W, Pluss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Klin Padiatr. 1998;210:192-199
Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H, ALL-BFM Study Group. Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Klin Pädiatr 1998, 210: 192
Schrappe M, Reiter A, Ludwig W-D, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H. Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: Results of trial ALL-BFM 90. Blood 2000, 95: 3310-22
Schrappe M, Reiter A, Riehm H. Prophylaxis and treatment of meningeosis in childhood acute lymphoblastic leukemia.J Neuro-Oncol 1998, 38: 159
Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205-22
Schrappe M, Riehm H. Akute lymphoblastische Leukämie im Kindesalter. In: Schmoll H-J, Höffken K, Possinger K (eds): Kompendium Internistische Onkologie: Standards in Diagnostik und Therapie, Berlin, Springer, 1999, 2233
Schünemann HJ, Stanulla M, Trevisan M, Aplan PD, Freudenheim JL, Muti P. Short-term storage of blood samples and DNA isolation in serum separator tubes for application in epidemiological studies and clinical research. Ann Epidemiol 2000, 10: 538-44
Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, Ritter J, Schwabe D, Harms D, Schrappe M, Henze G.TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 1998, 91: 1716
Seriu T, Takeuchi S, Koike M, Slater J, Park S, Miller CW, Schrappe M, Reiter A, Zimmermann M, Mori N, Kubota T, Golub TR, Gilliland DG, Miyoshi I, Koeffler HP, Bartram CR. Frequent loss of heterozygosity on chromosomes 6q, 9p, 11q or 12p in childhood acute lymphoblastic leukemia. In Hiddemann W, Büchner T, Creutzig U, Ritter J, Wörmann B (eds): Acute leukemia VII, Berlin, Heidelberg, New York, Springer, 1998
Stanulla M, Kasper B, Schrappe M, Viehmann S, Harbott J, Ludwig WD, Welte K. Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life. Leukemia 2000, 14: 337
Stanulla M, Löning L, Welte K, Schrappe M. Secondary brain tumours in children with ALL.Lancet 1999, 354:1126
Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 2000, 95: 1222-8
Stanulla M, Schrauder A, Welte K, Schrappe M. Tumor necrosis factor and lymphotoxin -alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy. BMC Blood Disord. 2001;1-2
Stanulla M, Stumm M, Dieckvoss BO, Seidemann K, Schemmel V, Müller-Brechlin A, Schrappe M, Welte K, Reiter A. No evidence for a major role of heterozygous deletion 657del5 within the NBS1 gene in the pathogenesis of non-Hodgkin's lymphoma of childhood and adolescence. Br J Haematol 2000, 109: 117-120
Stanulla M, Wang J, Chervinsky D.S, Thandla S, Aplan PD.DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 1997, 17: 4070-4079
Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JW, Reiter A, Ludwig WD, Zimmermann M, Schwaller J. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 1995;86:755-760
Takeuchi S, Bartram CR, Wada M, Reiter A, Hatta Y, Seriu T, Lee E, Miller CW, Miyoshi I, Koeffler HP. Allelotype analysis of childhood acute lymphoblastic leukemia. Cancer Res. 1995;55:5377-5382
Takeuchi S, Cho SK, Seriu T, Koike M, Bartram CR, Reiter A, Schrappe M, Takeuchi C, Taguchi H, Koeffler HP. Identification of three distinct regions of deletion on the long arm of chromosome 11 in childhood acute lymphoblastic leukemia. Oncogene 1999, 18: 7387
Takeuchi S, Koike M, Seriu T, Bartram CR, Schrappe M, Reiter A, Park S, Taub HE, Kubonishi I, Miyoshi I, Koeffler HP.Frequent loss of heterozygosity on the long arm of chromosome 6: identification of two distinct regions of deletion in childhood acute lymphoblastic leukemia. Cancer Res 1998, 58: 2618
van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig W-D, Basso G, de Bruijn MAC, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram CR. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia: A prospective study of the International BFM Study Group. Lancet 1998, 352: 1731
Vieira Pinheiro JP, Ahlke E, Nowak-Göttl U, Hempel G, Müller HJ, Lümkemann K, Schrappe M, Rath B, Fleischhack G, Mann G, Boos J. Pharmakokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999, 104: 313
Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, Riehm H. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood. 1996;87:3143-50
Willemse MJ, Seriu T, Hettinger K, d'Aniello E, Hop WC, Panzer-Grumayer ER, Biondi A, Schrappe M, Kamps WA, Masera G, Gadner H, Riehm H, Bartram CR, van DJ. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood. 2002;99:4386-93
Wuchter C, Karawajew L, Ruppert V, Schrappe M, Harbott J, Ratei R, Dorken B, Ludwig WD. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol. 2000;110:154-60.
Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, Haferlach T, Harbott J, Ratei RDr, B., Ludwig W. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000;85:711-21
Wuchter C, Ruppert V, Schrappe M, Dorken B, Ludwig WD, Karawajew
L. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic
cell death in context of maturation stage, responsiveness to interleukin
7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic
leukemia. Blood. 2002;99:4109-15.
Weitere Publikationen: PubMed Literaturdatenbank
